Cottin, Vincent

Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis

Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisChronic Obstructive Pulmonary Disease (COPD) Research

Cited by 4,654

Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline

Raghu, G., Remy-Jardin, M., Myers, J. L., Richeldi, L., Ryerson, C. J., Lederer, D. J., Behr, J., Cottin, V., Danoff, S. K., Morell, F., et al. (2018) · American Journal of Respiratory and Critical Care Medicine

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisOccupational and environmental lung diseases

Cited by 4,103

Nintedanib in Progressive Fibrosing Interstitial Lung Diseases

Flaherty, K. R., Wells, A. U., Cottin, V., Devaraj, A., Walsh, S. L. F., Inoue, Y., Richeldi, L., Kolb, M., Tetzlaff, K., Stowasser, S., et al. (2019) · New England Journal of Medicine

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisSystemic Sclerosis and Related Diseases

Cited by 2,403

Tuberous Sclerosis Complex Diagnostic Criteria Update: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference

Northrup, H., Krueger, D. A., Northrup, H., Krueger, D. A., Roberds, S., Smith, K., Sampson, J., Korf, B., Kwiatkowski, D. J., Mowat, D., et al. (2013) · Pediatric Neurology

Tuberous Sclerosis Complex ResearchGenetic and rare skin diseases.

Cited by 1,502

Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report

Collard, H. R., Ryerson, C. J., Corte, T. J., Jenkins, G., Kondoh, Y., Lederer, D. J., Lee, J. S., Maher, T. M., Wells, A. U., Antoniou, K. M., et al. (2016) · American Journal of Respiratory and Critical Care Medicine

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisChronic Obstructive Pulmonary Disease (COPD) Research

Cited by 1,444

Spectrum of fibrotic lung diseases

Wijsenbeek, M., & Cottin, V. (2020) · New England Journal of Medicine

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisSystemic Sclerosis and Related Diseases

Cited by 736

Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial

Maher, T. M., Corte, T. J., Fischer, A., Kreuter, M., Lederer, D. J., Molina-Molina, M., Axmann, J., Kirchgaessler, K.-U., Samara, K., Gilberg, F., et al. (2020) · The Lancet Respiratory Medicine

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisSystemic Sclerosis and Related Diseases

Cited by 629

European Respiratory Society guidelines for the diagnosis and management of lymphangioleiomyomatosis

Johnson, S. R., Cordier, J. F., Lazor, R., Cottin, V., Costabel, U., Harari, S., Reynaud-Gaubert, M., Boehler, A., Brauner, M., Popper, H., et al. (2010) · European Respiratory Journal

Tuberous Sclerosis Complex ResearchMedical Imaging and Pathology Studies

Cited by 590

Eosinophilic granulomatosis with polyangiitis (Churg–Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management

Groh, M., Pagnoux, C., Baldini, C., Bel, E., Bottero, P., Cottin, V., Dalhoff, K., Dunogué, B., Gross, W., Holle, J., et al. (2015) · European Journal of Internal Medicine

Vasculitis and related conditionsEosinophilic Disorders and Syndromes

Cited by 476

Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS® trials

Richeldi, L., Cottin, V., du Bois, R. M., Selman, M., Kimura, T., Bailes, Z., Schlenker-Herceg, R., Stowasser, S., & Brown, K. K. (2016) · Respiratory Medicine

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisChronic Obstructive Pulmonary Disease (COPD) Research

Cited by 463

Treatment of Idiopathic Pulmonary Fibrosis with Etanercept: An Exploratory, Placebo-controlled Trial

Raghu, G., Brown, K. K., Costabel, U., Cottin, V., du Bois, R. M., Lasky, J. A., Thomeer, M., Utz, J. P., Khandker, R. K., McDermott, L., et al. (2008) · American Journal of Respiratory and Critical Care Medicine

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisChronic Obstructive Pulmonary Disease (COPD) Research

Cited by 370

Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities

George, P. M., Spagnolo, P., Kreuter, M., Altinisik, G., Bonifazi, M., Martinez, F. J., Molyneaux, P. L., Renzoni, E. A., Richeldi, L., Tomassetti, S., et al. (2020) · The Lancet Respiratory Medicine

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisSystemic Sclerosis and Related Diseases

Cited by 349

Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis.

Richeldi, L., Azuma, A., Cottin, V., Kreuter, M., Maher, T. M., Martinez, F. J., Oldham, J. M., Valenzuela, C., Clerisme-Beaty, E., Gordat, M., et al. (2025) · New England Journal of Medicine

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisPulmonary Hypertension Research and Treatments

Cited by 297

The natural history of progressive fibrosing interstitial lung diseases

Brown, K. K., Martinez, F. J., Walsh, S. L. F., Thannickal, V. J., Prasse, A., Schlenker-Herceg, R., Goeldner, R.-G., Clerisme-Beaty, E., Tetzlaff, K., Cottin, V., et al. (2020) · European Respiratory Journal

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisOccupational and environmental lung diseases

Cited by 293

Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial

Raghu, G., Brown, K. K., Collard, H. R., Cottin, V., Gibson, K. F., Kaner, R. J., Lederer, D. J., Martinez, F. J., Noble, P. W., Song, J. W., et al. (2017) · The Lancet Respiratory Medicine

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisChronic Obstructive Pulmonary Disease (COPD) Research

Cited by 278

Tuberous Sclerosis registry to increase disease Awareness (TOSCA): baseline data on 2093 patients

on behalf of TOSCA consortium and TOSCA investigators, Kingswood, J. C., d’Augères, G. B., Belousova, E., Ferreira, J. C., Carter, T., Castellana, R., Cottin, V., Curatolo, P., Dahlin, M., et al. (2017) · Orphanet Journal of Rare Diseases

Tuberous Sclerosis Complex ResearchGenetic and rare skin diseases.

Cited by 267

Trial of a Preferential Phosphodiesterase 4B Inhibitor for Idiopathic Pulmonary Fibrosis

Richeldi, L., Azuma, A., Cottin, V., Hesslinger, C., Stowasser, S., Valenzuela, C., Wijsenbeek, M. S., Zoz, D. F., Voss, F., & Maher, T. M. (2022) · New England Journal of Medicine

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisPhosphodiesterase function and regulation

Cited by 236

Revisiting the systemic vasculitis in eosinophilic granulomatosis with polyangiitis (Churg-Strauss)

Cottin, V., Bel, E., Bottero, P., Dalhoff, K., Humbert, M., Lazor, R., Sinico, R. A., Sivasothy, P., Wechsler, M. E., Groh, M., et al. (2017) · Autoimmunity Reviews

Vasculitis and related conditionsOtitis Media and Relapsing Polychondritis

Cited by 175

Combination therapy: the future of management for idiopathic pulmonary fibrosis?

Wuyts, W. A., Antoniou, K. M., Borensztajn, K., Costabel, U., Cottin, V., Crestani, B., Grutters, J. C., Maher, T. M., Poletti, V., Richeldi, L., et al. (2014) · The Lancet Respiratory Medicine

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisChronic Obstructive Pulmonary Disease (COPD) Research

Cited by 150

Ziritaxestat, a Novel Autotaxin Inhibitor, and Lung Function in Idiopathic Pulmonary Fibrosis: The ISABELA 1 and 2 Randomized Clinical Trials

Maher, T. M., Ford, P., Brown, K. K., Costabel, U., Cottin, V., Danoff, S. K., Groenveld, I., Helmer, E., Jenkins, R. G., Milner, J., et al. (2023) · JAMA

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisChronic Obstructive Pulmonary Disease (COPD) Research

Cited by 148

Long-term safety of pirfenidone: results of the prospective, observational PASSPORT study

Cottin, V., Koschel, D., Günther, A., Albera, C., Azuma, A., Sköld, C. M., Tomassetti, S., Hormel, P., Stauffer, J. L., Strombom, I., et al. (2018) · ERJ Open Research

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisPharmacovigilance and Adverse Drug Reactions

Cited by 121

Clinical characteristics and survival in systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease

Launay, D., Humbert, M., Berezne, A., Cottin, V., Allanore, Y., Couderc, L.-J., Bletry, O., Yaici, A., Hatron, P.-Y., Mouthon, L., et al. (2011) · Chest

Pulmonary Hypertension Research and TreatmentsSystemic Sclerosis and Related Diseases

Cited by 99

Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis: The INTEGRIS-IPF Clinical Trial

Lancaster, L., Cottin, V., Ramaswamy, M., Wuyts, W. A., Jenkins, R. G., Scholand, M. B., Kreuter, M., Valenzuela, C., Ryerson, C. J., Goldin, J., et al. (2024) · American Journal of Respiratory and Critical Care Medicine

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisChronic Obstructive Pulmonary Disease (COPD) Research

Cited by 80

Efficacy and Safety of Admilparant, an LPA1 Antagonist, in Pulmonary Fibrosis: A Phase 2 Randomized Clinical Trial.

Corte, T. J., Behr, J., Cottin, V., Glassberg, M. K., Kreuter, M., Martinez, F. J., Ogura, T., Suda, T., Wijsenbeek, M., Berkowitz, E., et al. (2025) · American Journal of Respiratory and Critical Care Medicine

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisPulmonary Hypertension Research and Treatments

Cited by 70